Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
Chiu CS, Peekhaus N, Weber H, Adamski S, Murray EM, Zhang HZ, Zhao JZ, Ernst R, Lineberger J, Huang L, Hampton R, Arnold BA, Vitelli S, Hamuro L, Wang WR, Wei N, Dillon GM, Miao J, Alves SE, Glantschnig H, Wang F, Wilkinson HA. Chiu CS, et al. Among authors: glantschnig h. J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1181-92. doi: 10.1093/gerona/glt030. Epub 2013 Mar 22. J Gerontol A Biol Sci Med Sci. 2013. PMID: 23525481
Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo.
Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, Ernst R, Wei N, Nantermet P, Scott KR, Fisher JE, Talamo F, Orsatti L, Reszka AA, Sandhu P, Kimmel D, Flores O, Strohl W, An Z, Wang F. Glantschnig H, et al. J Biol Chem. 2010 Dec 17;285(51):40135-47. doi: 10.1074/jbc.M110.166892. Epub 2010 Oct 7. J Biol Chem. 2010. PMID: 20929859 Free PMC article.
A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody.
Glantschnig H, Scott K, Hampton R, Wei N, McCracken P, Nantermet P, Zhao JZ, Vitelli S, Huang L, Haytko P, Lu P, Fisher JE, Sandhu P, Cook J, Williams D, Strohl W, Flores O, Kimmel D, Wang F, An Z. Glantschnig H, et al. J Pharmacol Exp Ther. 2011 Aug;338(2):568-78. doi: 10.1124/jpet.111.181404. Epub 2011 Apr 29. J Pharmacol Exp Ther. 2011. PMID: 21531794
Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis.
Ma B, Luo B, Euler DH, Cusick TE, Wesolowski G, Glantschnig H, Duong LT, Ou Y, Carroll SS, Lubbers LS. Ma B, et al. Among authors: glantschnig h. Naunyn Schmiedebergs Arch Pharmacol. 2017 Apr;390(4):435-441. doi: 10.1007/s00210-017-1356-5. Epub 2017 Feb 20. Naunyn Schmiedebergs Arch Pharmacol. 2017. PMID: 28220210 Clinical Trial.
31 results